A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Latest Information Update: 09 Nov 2022
At a glance
- Drugs Levoketoconazole (Primary)
- Indications Cushing syndrome
- Focus Registrational; Therapeutic Use
- Acronyms LOGICS
- Sponsors Strongbridge Biopharma; Xeris Biopharma Holdings
- 12 May 2022 According to a Xeris Biopharma Holdings media release, data from this study will be presented at the American Association of Clinical Endocrinology (AACE) Annual Meeting, 2022.
- 12 May 2022 Results presented in the Xeris Biopharma Holdings Media Release.
- 30 Dec 2021 According to a Xeris Biopharma Holdings media release, the FDA decision follows successful completion of acquisition of Strongbridge Biopharma on October 5, 2021.